MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed B-cell or T-cell lymphoma
• * Hodgkin's lymphoma and anaplastic large cell lymphoma eligible
• * No HIV-associated lymphoma
• CD30-positive disease by biopsy, flow cytometry, or immunohistochemistry
• * At least 50% of malignant cells (specifically Reed-Sternberg cells for Hodgkin's lymphoma) must express CD30
• Must meet one of the following criteria for relapsed/refractory disease:
• * Relapsed after prior chemotherapy or radiotherapy and autologous or allogeneic bone marrow transplantation (if appropriate)
• * Relapsed disease must be within the prior irradiated field
• * Disease that is refractory to prior chemotherapy or radiotherapy with no other curative treatment option
• * Disease progression must be within the prior irradiated field
• Progressive and evaluable disease (measurable disease required for patients accrued on study after the maximum tolerated dose is determined)
• PATIENT CHARACTERISTICS:
• Age
• Over 12
• Performance status
• ECOG 0-2
• Life expectancy
• At least 12 weeks
• Hematopoietic
• WBC at least 1,500/mm\^3\*
• Neutrophil count at least 1,000/mm\^3\*
• Platelet count at least 75,000/mm\^3\*
• Hemoglobin at least 8.0 g/dL\* NOTE: \*Laboratory abnormalities attributable to organ involvement by lymphoma are allowed
• Hepatic
• AST no greater than 2 times upper limit of normal (ULN)\*
• Bilirubin no greater than 2.0 mg/dL (unless due to Gilbert's syndrome)\*
• Hepatitis B surface antigen negative
• Hepatitis C antibody negative NOTE: \*Laboratory abnormalities attributable to organ involvement by lymphoma are allowed
• Renal
• Creatinine no greater than 2 times ULN\* NOTE: \*Laboratory abnormalities attributable to organ involvement by lymphoma are allowed
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective barrier contraception during and for 9 months after study participation
• HIV negative
• No other active malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
• No active significant infection
• No apparent opportunistic infection, as indicated by any of the following:
• * Purified protein derivative recently determined to be positive
• * Infectious infiltrate by chest x-ray
• * Recent changes in fever/chill patterns
• * New, unexplained neurological symptoms
• No underlying medical condition that would preclude receiving study therapy
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• See Disease Characteristics
• No prior anti-CD30 antibody therapy
• No other concurrent biologic therapy
• Chemotherapy
• See Disease Characteristics
• At least 4 weeks since prior chemotherapy
• No concurrent chemotherapy
• Endocrine therapy
• No concurrent systemic steroidal therapy (excluding physiologic doses)
• Radiotherapy
• See Disease Characteristics
• At least 4 weeks since prior radiotherapy
• No concurrent radiotherapy
• Surgery
• Not specified
• Other
• No other concurrent investigational agents